News Biogen pens $1bn deal to buy immunology biotech RayThera Biogen has agreed its second takeover deal of 2026, an acquisition of immunology start-up RayThera valued at up to $1 billion.
Patients ASCO 2026: New hope in AL amyloidosis, with Dr Hans Lee A phase 1/2 trial in AL amyloidosis saw 100% of patients obtaining at least a very good partial response with 90% obtaining a complete response.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
